Mpairwe, HarrietWebb, Emily L.Muhangi, LawrenceNdibazza, JulietAkishule, DeniseNampijja, MargaretNgom-wegi, SophyTumusime, JosephineJones, Frances M.Fitzsimmons, ColinDunne, David W.Muwanga, MosesRodrigues, Laura C.Elliott, Alison M.2022-01-302022-01-302011Mpairwe H, Webb EL, Muhangi L, Ndibazza J, Akishule D, Nampijja M, Ngom-wegi S, Tumusime J, Jones FM, Fitzsimmons C, Dunne DW, Muwanga M, Rodrigues LC, Elliott AM. Anthelminthic treatment during pregnancy is associated with increased risk of infantile eczema: randomised-controlled trial results. Pediatr Allergy Immunol 2011; 22: 305–312. DOI:10.1111/j.1399-3038.2010.01122.x10.1111/j.1399-3038.2010.01122.xhttps://nru.uncst.go.ug/xmlui/handle/123456789/1625Allergy is commoner in developed than in developing countries. Chronic worm infections show inverse associations with allergy, and prenatal exposures may be critical to allergy risk. To determine whether anthelminthic treatment during pregnancy increases the risk of allergy in infancy. A randomized, double-blind, placebo-controlled trial on treatment in pregnancy with albendazole versus placebo and praziquantel versus placebo was conducted in Uganda, with a 2 · 2 factorial design; 2507 women were enrolled; infants’ allergy events were recorded prospectively. The main outcome was doctor-diagnosed infantile eczema.enAlbendazolePraziquantelWormsInfantile eczemaPregnancyClinical trialsArticle